Abstract
The percent and absolute lumbar spine and femoral neck bone mineral densities and procollagen type I N-terminal propeptide (PINP) and urinary N-telopeptide level increases noted after teriparatide 20μg/day treatment for 24months were similar in the older (age ≥ 80years) and younger (age < 80years) subgroups. Many individuals are living into their eighth and ninth decades, but little is known about the efficacy of osteoporosis medication for this population. We retrospectively compared usefulness of daily teriparatide therapy in osteoporosis patients ≥80 and <80years to detect possible age-related differences. We analyzed 628 osteoporosis patients treated with teriparatide 20μg/day for 24months. The primary efficacy measures were changes in lumbar spine (LS) and femoral neck (FN) bone mineral density (BMD) over 24months. Changes in serum procollagen type I N-terminal propeptide levels and urinary N-telopeptide (uNTX) excretion were also measured. Patients were divided into age subgroups (older, ≥80years; younger, <80years) for BMD and bone turnover marker comparison. In the older subgroup, the percent LS BMD significantly increased by 14.6 ± 10.4% (mean ± SD) and FN BMD significantly increased by 4.5 ± 10.7% at 24months. In the younger subgroup, the percent LS BMD significantly increased by 12.2 ± 8.5% and FN BMD significantly increased by 2.9 ± 8.3% at 24months. In the older subgroup, the mean absolute LS BMD change was 0.111 ± 0.071g/cm(2) and FN BMD change was 0.019 ± 0.043g/cm(2). In the younger subgroup, the mean absolute LS BMD change was 0.098 ± 0.065g/cm(2) and FN BMD change was 0.016 ± 0.045g/cm(2). The percent and absolute BMD increases in LS and FN and changes in PINP and uNTX were similar between the subgroups. The usefulness of daily teriparatide treatment is not age dependent.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call